Understanding LAG-3 Signaling

Luísa Chocarro 1, Ester Blanco 1, Miren Zuazo 1, Hugo Arasanz 1,2, Ana Bocanegra 1, Leticia Fernández-Rubio 1, Pilar Morente 1, Gonzalo Fernández-Hinojal 1,2, Miriam Echaide 1, Maider Garnica 1, Pablo Ramos 1, Ruth Vera 2, Grazyna Kochan 1,* and David Escors 1,*

Oncoimmunology Group, Navarrabiomed-Public University of Navarre, IdISNA, 31008 Pamplona, Navarra, Spain; luisa.chocarro.deerauso@navarra.es (L.C.); ester.blanco.palmeiro@navarra.es (E.B.); mzuazo@alumni.unav.es (M.Z.); hugo.arasanz.estebar@navarra.es (H.A.); abocaneg@navarra.es (A.B.); leticia.fernandez.rubio@navarra.es (L.F.-R.); pilar.morente.sancho@navarra.es (P.M.); gfhinoj@navarro.ek (G.F.-H.); mecha@navarra.es (M.E.); mgarnic@navarra.es (M.G.); pramosca@navarra.es (P.R.)

2 Department of Medical Oncology, Complejo Hospitalario de Navarra CHN-IdISNA, 31008 Pamplona, Navarra, Spain; ruth.venica.garcia@navarra.es

* Correspondence: grazyna.kochan@navarra.es (G.K.); david.escors.murugarren@navarra.es (D.E.)

Received: 22 April 2021  
Accepted: 13 May 2021  
Published: 17 May 2021

Citation: Chocarro, L.; Blanco, E.; Zuazo, M.; Arasanz, H.; Bocanegra, A.; Fernández-Rubio, L.; Morente, P.; Fernández-Hinojal, G.; Echaide, M.; Garnica, M.; et al. Understanding LAG-3 Signaling. Int. J. Mol. Sci. 2021, 22, 5282. https://doi.org/10.3390/ijms22105282

Abstract: Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. LAG-3 is the third inhibitory receptor to be exploited in human anti-cancer immunotherapies, and it is considered a potential next-generation cancer immunotherapy target in human therapy, right next to PD-1 and CTLA-4. Unlike PD-1 and CTLA-4, the exact mechanisms of action of LAG-3 and its relationship with other immune checkpoint molecules remain poorly understood. This is partly caused by the presence of non-conventional signaling motifs in its intracellular domain that are different from other conventional immunoregulatory signaling motifs but with similar inhibitory activities. Here we summarize the current understanding of LAG-3 signaling and its role in LAG-3 functions, from its mechanisms of action to clinical applications.

Keywords: LAG-3; immune checkpoint; cancer signaling; immunotherapy; targeted therapy

1. Molecular Characterization of LAG-3

1.1. Function

LAG-3 (CD223) is an inhibitory receptor first described in in vitro-activated T cells. LAG-3 has multiple biological effects on the function of T cells and CD4 T cell activation, usually inhibitory [1,2]. LAG-3 does not seem to inhibit T cell function in the absence of CD4 activation but may interfere with CD4 coreceptor function. LAG-3 negatively regulates proliferation, activation, effector function, and homeostasis of both CD8 and CD4 T cells, as shown in LAG-3 knockout mice and by LAG-3 blockade with antibodies in human cells [1,3–5]. Thus, the evidence suggests that LAG-3 interferes with a common pathway to both CD4 and CD8 activation and regulates the activation and expansion of T memory cells [6].

LAG-3 plays a regulatory role in the immune system comparable to PD-1 and CTLA-4, generally consisting of inhibition of cell proliferation, immune function, cytokine secretion, and homeostasis [1–3,7]. LAG-3 can be upregulated under various antigen stimulation conditions [3,8,9]. Its expression is induced by TCR stimulation or cytokine stimulation, and LAG-3 is upregulated within activated, cytokine-expressing T cells [9–12]. LAG-3 associates with the TCR-CD3 complex at the T cell membrane and negatively regulates...
TCR signal transduction, which in turn terminates cell proliferation and cytokine secretion in response to CD3 signaling [13]. LAG-3 and CD3 co-engagement in the immunological synapse is necessary to down-modulate TCR signal transduction. Among other consequences, the simultaneous engagement of LAG-3/TCR with their ligands inhibits TCR:CD3-dependent intracellular calcium fluxes. Similarly to PD-1, constitutive LAG-3 expression is frequently associated with exhausted T cells, and it is generally regarded as an exhaustion marker for CD4 and CD8 T cells in response to repetitive antigen stimulation in cancer and chronic viral infections [14–19]. Indeed, LAG-3 has been found to physically associate with TCR in both CD8 and CD4 T cells following TCR engagement, down-regulating TCR-dependent signaling cascades and thereby dampening T cell responses [13] (Figure 1).

![Figure 1. Schematic representation of the molecular interactions occurring within the immunological synapse between a T cell and an antigen-presenting cell (APC) during antigen presentation and T cell activation. The TCR/CD3 and MHC complexes are highlighted in yellow. Some of the well-known co-stimulatory and co-inhibitory receptor–ligand interactions are shown in the figure, linked by red lines for activating interactions and with blue lines for inhibitory interactions. Antigenic peptides presented by APCs loaded in MHC molecules are specifically recognized by the TCR, while other interactions take place simultaneously to deliver co-stimulatory and co-inhibitory signals. These interactions are integrated within T cells. The LAG-3 molecule is highlighted in blue.](image)

1.2. Genetic Structure of the LAG-3 Gene and Domain Organization

Back in 1990, Dr. Frédéric Triebel and colleagues identified lag-3 as a novel lymphocyte activation gene closely related to CD4. The authors found a 2-kb mRNA to be selectively transcribed in activated human T and NK cells [8]. Lag-3 encodes a protein with a molecular weight of 70 kDa and resides on the distal part of the short arm of chromosome 12 (12p13.32) in humans and in chromosome 6 in mouse. The lag-3 gene encodes a 498-amino acid type I membrane protein [20]. Its locus is adjacent to that of the CD4 co-receptor and has a similar sequence and intron/exon organization, strongly indicating that lag-
3 and CD4 genes have evolved by gene duplication from a pre-existing common evolutionary ancestor gene encoding a two-IgSF-domain structure.

The LAG-3 protein structure can be divided into extracellular, transmembrane, and intracellular regions (Figure 2). The gene has 8 exons. Exon I encodes 19 aa of the hydrophobic leader peptide; exon II encodes 9 aa of the leader peptide (9 aa) and 41 aa of the extracellular region (41 aa); the rest of the extracellular region is encoded by exon III (101 aa), IV (90 aa), V (92 aa), and VI (81 aa); exon VII encodes the transmembrane region (44 aa); and exon VIII (21 aa), the highly charged cytoplasmic region [8].

Figure 2. Molecular organization of CD4 and LAG-3 proteins. The domain organization of CD4 and LAG-3 is schematically shown in the figure, with each Ig-like domain indicated as arcs. Dotted lines represent disulfide bonds. The cleavage site for ADAM 10/17 in LAG-3 is shown, rendering a soluble version. CP: connecting peptide; SP: signal peptide.

The LAG-3 protein corresponds to a mature protein of 525 residues with a molecular mass of approximately 50 kDa. Both CD4 and LAG-3 extracellular regions are composed of four extracellular immunoglobulin superfamily-like (IgSF) domains (D1-D4) (Figure 2). D1 is an Ig variable-like region (V-SET type), and it includes an extra, unique, proline-rich loop (30 residues) in the middle of the domain (between the C and C′β strands of the D1 domain) and an unusual intra-chain disulfide bridge [8]. Unlike CD4, this loop mediates LAG-3–MHCII interactions [21]. Domains D2, D3, and D4 of LAG-3 belong to the C2-SET, while the CD4 D3 domain is of a V-SET type. D1 and D3 of LAG-3, as well as D2 and D4, share strong internal structural homologies. However, CD4 and LAG-3 only share less than 20% amino acid sequence homology. A β-strand between D1 and D2 and between D3 and D4 extends rigidly between these substructures [20].

Additionally, compared to CD4, the LAG-3 protein has a longer connecting peptide between the membrane-proximal D4 domain and the transmembrane region. LAG-3 is cleaved within this connecting peptide, resulting in the release of a soluble form [21]. This cleavage has been described to be mediated by two transmembrane metalloproteases, ADAM10 and ADAM17, regulated through two distinct mechanisms. While ADAM10 mediates constitutive LAG-3 cleavage, ADAM17 mediates LAG-3 cleavage induced by TCR signaling in a PKCθ-dependent manner [22]. Interestingly, there is evidence that shedding of LAG-3 from the cell surface enhances T-cell proliferation and effector function, which adds another activating level of immune regulation by LAG-3 [21,22].

The cytoplasmic tail of LAG-3 mediates intracellular negative signal transduction, as its deletion completely abrogates its inhibitory function. The cytoplasmic tail contains three conserved motifs (Figure 2): (1) a potentially phosphorylatable serine (S484), (2) a KIEELE motif, and (3) a glutamate-proline dipeptide multiple repeats motif (EP motif). Nevertheless, there is conflicting evidence on how these motifs affect LAG-3 molecular function and downstream signaling. The potential serine phosphorylation motif (S484) has been described within the FxxL motif, although no specific function has been ascribed
to it other than its correlation with IL-2 production. This serine may be analogous to the protein kinase C binding site in the CD4 molecule [23].

The KIEELE motif corresponds to a highly conserved short sequence not found in other proteins, and its relevance to LAG-3 function remains controversial. According to Workman et al., the deletion of KIEELE completely abrogates LAG-3 function on CD4 T cells, highlighting its importance for LAG-3 inhibitory signaling [3,24]. In addition, an alanine scanning mutagenesis of KIEELE residues showed that lysine residue (K468) was absolutely required for LAG-3 downstream signaling, with minor contributions by E470 and E471 in CD4 function. However, according to Maeda and colleagues, LAG-3 mediates a cell-intrinsic, negative inhibitory signal independently of KIEELE via two distinct mechanisms that are dependent on the FxxL motif in the membrane proximal region and the carboxy-terminal EP repeats [25].

The EP repeat motif is present in some proteins in diverse species and cellular locations, which could be an indicator of a potentially common biological function. For example, PDGF-R, LckBP1, and SPY75 contain similar EP regions that contribute to their signaling mechanisms. It was proposed that the EP motif was key in counteracting the CD3/TCR activation pathway via association to LAP protein (LAG-3 associated protein), allowing LAG-3 co-localization with CD3, CD4, and CD8 within lipid rafts [26]. According to Workman and colleagues, the deletion of the EP motif or the S484A mutation maintained LAG-3 activity and function in CD4+ and CD4− T cells, suggesting that these two features may not have been essential [3]. Nevertheless, it has to be stressed that the inhibitory activity of LAG-3 was only completely abrogated in CD4+ T cells if both KIEELE and EP motifs were removed. The authors proposed that the EP motif could play a role in preventing LAG-3 from acting as a stimulatory co-receptor such as CD4 rather than cooperating with KIEELE in inhibitory signal transduction.

As LAG-3 is localized in lipid rafts following antigen stimulation [26], its cytoplasmic domain could be mediating its location in the cell membrane. LAG-3 co-localizes with glycosphingolipid-enriched microdomain complexes containing CD3, CD4, or CD8. After TCR engagement, LAG-3 co-localizes with CD3 and ganglioside GM1 in the immunological synapse. However, no systematic follow-up studies on these motifs and their functions have been reported to date. The structural nature of LAG-3 needs to be elucidated to understand its mechanisms of action on the regulation of T cell activation.

Apart from its surface expression, LAG-3 can also be stored in lysosomes, and it is translocated to the membranes of activated T cells via its cytoplasmic domain by protein kinase C signaling [27].

1.3. LAG-3 Ligands

MHC-II molecules are considered the canonical ligand of LAG-3, with which it stably interacts through the D1 domain with a significantly higher affinity than with CD4 [20]. This association negatively regulates T cell activation, cytotoxicity, and cytokine production [28]. In fact, LAG-3-Ig fusion proteins act as competitors in CD4/MHC class II-dependent cellular adhesion assays [29]. Once LAG-3 is bound to MHC-II, it transmits inhibitory signals via its cytoplasmic domain and inhibits CD4 T cell activation [1,2]. Nevertheless, the molecular mechanisms of signal transduction remain broadly unknown compared to other immune checkpoint molecules. LAG-3:MHC class II binding contributes to tumor escape from apoptosis [30] and facilitates recruitment of tumor-specific CD4 T cells, but with a reduction of the CD8 T cell response [31].

Initially, the high-affinity LAG-3:MHC class II interaction was proposed to be the main mechanism of the inhibitory activities of LAG-3 through competition with CD4:MHC II binding [1,2]. However, it still remains controversial whether the interaction with MHC-II is solely responsible for mediating LAG-3 immunosuppressive functions, in light of the recent identification of additional ligands.
The second LAG-3 ligand to be described was galectin-3 (Gal-3), a 31 kDa galactose-binding lectin that modulates T cell activation. Gal-3 has been shown to be highly expressed in various tumor cells and in activated T lymphocytes [32–35]. Gal-3 binds to LAG-3 and appears to be required for optimal inhibition of CD8 T cell cytotoxic function. Gal-3 shapes antitumor-specific immune responses by suppressing activated antigen-committed CD8 T cells via LAG-3 expression in the tumor microenvironment and inhibiting expansion of plasmacytoid dendritic cells [35].

The liver-secreted protein fibrinogen-like protein 1 (FGL1) was recently identified as a new LAG-3 functional ligand [36]. FGL1 is a member of the fibrinogen family and possesses immunosuppressive activities by inhibiting antigen-specific T cells through LAG-3 binding. FGL1 interacts with LAG-3 via the fibrinogen-like domain with the D1 and D2 Ig-like domains of LAG-3. Its expression is induced by IL-6 and is highly up-regulated in several human cancers such as lung cancer, prostate cancer, melanoma, and colorectal cancer. Indeed, it was demonstrated that elevated plasma FGL1 levels were associated with poor cancer outcomes and anti-PD-1 therapy resistance [36]. Thus, this binding was described as a novel mechanism of immune evasion, and its blockade potentiated anti-tumor T cell immunity in pre-clinical models. The FGL1/LAG-3 blockade may synergize with anti-PD-1/anti-PD-L1 therapy. A single point mutation (Y73F) in the D1 C' strand domain of LAG-3 disrupted LAG-3/MHC-II binding [3,4,20], but not FGL1-Ig binding. Nevertheless, this mutant LAG-3 could still inhibit T cells, demonstrating that FGL1/LAG-3 interactions correspond to a tumor immune evasion mechanism which is non-redundant to MHC-II binding.

Taken together, these data suggest that LAG-3 interactions with several ligands are important for its inhibitory function, and unlike what was thought before, LAG-3 does not function primarily by disrupting CD4:MHC-II interactions.

2. Regulation of LAG-3 Expression

2.1. Cell and Tissue Expression

LAG-3 expression has been characterized by multiple studies in murine cells, in human blood cells, and other tissues (Figure 3). LAG-3 is expressed by different T cell subsets such as activated CD4 T helper (Th) and cytotoxic CD8 T cells (CTL) [37]. LAG-3 is expressed by most of the activated CD4 differentiation subsets (Th1, Th0) with the exception of Th2. T cell activation seems to be a requirement for LAG-3 expression on the cell surface [27]. LAG-3 expression is also upregulated by cytokines such as IL-2 and IL-12 on activated T cells [10,38,39], and its expression correlates with increased IL-10 production [40]. Surface LAG-3 protein expression and LAG-3 shedding by activated CD4 human T cells strongly correlates with IFN-γ production, a potent MHC-II inducer. In addition, LAG-3 expression inversely correlates with IL-4 production [10]. LAG-3 co-localizes with CD3 and CD4/CD8 clusters after its translocation to the membrane through lipid rafts [6]. Tumor-infiltrating, antigen-specific CD8 T cells have been reported to be negatively regulated by LAG-3 in human ovarian cancer, and PD-1/LAG-3 co-expression in peripheral blood T cells is a biomarker of strong T cell dysfunctionality in lung cancer [41,42].
LAG-3 has also been described as being expressed by subsets of natural killer cells (NK) and invariant NK T cells. Indeed, the lag-3 locus is close to the NK gene complex, which is expressed on activated NK cells. However, LAG-3 does not participate in a specific mode of natural killing in human NK cells [8,9,43].

LAG-3 is expressed in activated effector CD4 T cells [44], and particularly in activated natural and inducible regulatory T cells (nTregs and iTregs, respectively). Foxp3\textsuperscript{CD25\textsuperscript{low}} IL-10\textsuperscript{+} type 1 regulatory T cells (Tr1) also highly express LAG-3 [45,46], and its co-expression with CD49b\textsuperscript{+} has been used as an identifying Tr1 feature [45–47]. In fact, it has been shown that the IL-27/LAG-3 axis enhances Treg suppressive function [48]. Overall, the evidence supports the requirement of LAG-3 expression for maximal suppressing functions of natural and inducible Tregs [13,49].

LAG-3 expression has also been described in exhausted CD8 PD1\textsuperscript{+} tumor-infiltrating lymphocytes (TILs) [44,45,50]. However, its role in immune escape is still controversial, as it has been described that LAG-3 expression in TILs is related to a positive prognosis in esophageal cancer, non-small cell lung cancer, Hodgkin’s lymphoma, and microsatellite instability-high colorectal cancer cases [51–54]. Expression of LAG-3 by TILs is related to suppression of antigen-specific CD8 T cell function [51]. In addition, LAG-3 co-expression with other immune checkpoint molecules such as CD274 and IDO1 in TILs serve as a prognostic biomarker for cancer prognosis [53].

LAG-3 expression on activated B cells has been described to be T cell-dependent [55]. High expression of LAG-3 has also been shown in chronic lymphocytic leukemia cells (CLL), characterized by clonal expansion of mature B-cells (CD5\textsuperscript{+} CD23\textsuperscript{+} CD27\textsuperscript{−} Ig\textsuperscript{low}). LAG-3 is also expressed by a natural regulatory plasma cell subset (LAG-3\textsuperscript{-}CD138\textsuperscript{hi} plasma cells, or Bregs), differentiated in a B cell receptor (BCR)-dependent manner [56]. Interestingly, this cell subset exhibits a distinct plasma cell-specific epigenomic/transcriptional signature and molecular program. In this case, bruton tyrosine kinase (Btk) and BCR signaling control the development of LAG-3\textsuperscript{+} Bregs independently of TLR signaling and T cell help. In contrast, Khshiebun and collaborators found that LAG-3 mRNA and protein expression in Epstein–Barr virus transformed B cells without T cell help [57].

There is evidence that LAG-3 can also be expressed by other cells not belonging to the lymphocytic lineage. This is the case in LAG-3 expression by plasmacytoid dendritic cells (pDCs). LAG-3 regulates CD11c\textsuperscript{low} B220\textsuperscript{+} PDCA-1\textsuperscript{+} pDC cell homeostasis in a selective
cell-intrinsic and cell-extrinsic manner. It has been shown that activated pDCs can even secrete about 5 times more soluble LAG-3 than activated T cells [14]. Although it is not expressed in more DC subsets, soluble LAG-3 causes effective phenotypical and functional maturation and activation of human monocyte-derived dendritic cells (DC) in the presence of GM-CSF and IL-4 [58]. In addition, LAG-3-induced matured DCs secrete IL-12 and TNF-α inflammatory cytokines and possess strong allostimulatory capacities. In fact, a LAG-3 fused to an immunoglobulin module has been used as a potent vaccine adjuvant due to its potent capacity to cause full maturation of human monocyte-derived DC.

Interestingly, LAG-3 has also been shown to be expressed in neurons, where it specifically binds to and co-endocytoses with pathologic α-synuclein [59–61].

### 2.2. Genetic and Epigenetic Regulation of LAG-3 Expression

Transcription from the lag-3 gene produces 4 transcripts or splice variants (lag3-201, lag3-202, lag3-203, lag3-204) (Table 1). Lag-3 genes can be classified into 190 orthologues (26 in primates, 30 in rodents, 33 in Laurasiatheria, 92 in all placental mammals, 14 in Sauropsida,) and 10 paralogues (IL18RAP, SIGIRR, IL1R2, IL1RL1, IL1RAPL2, IL18R1, IL1RAPL1, IL1RAP, IL1R1, IL1RL2). Lag-3 is a member of the 1 Ensembl protein family (PTHR11890 (the interleukin 1 receptor) and its precursor family) and of the Human CCDS set (CCDS8561.1). The lag-3 gene maps to 6,881,678-6,887,621 in GRCh37 coordinates (CM000674.1), and its locus corresponds to chromosome 12: 6,772,512-6,778,455 in the forward strand. The LAG-3 protein is assigned to the P18627 UniProtKB identifier.

| Transcript (ID)          | Length               | Biotype            | Location               | Exons | Annotation                      |
|-------------------------|----------------------|--------------------|------------------------|-------|---------------------------------|
| Lag3-201 (ENST00000203629.3) | Transcript length: 1976 bps Translation length: 525 residues | Protein coding     | Chromosome 12: 6,772,520-6,778,455 | 8 (all coding) | 24 domains and features 2174 variant alleles |
| Lag3-202 (ENST00000441671.6) | Transcript length: 1576 bps Translation length: 360 residues | Protein coding     | Chromosome 12: 6,772,519-6,775,733 | 5 (all coding) | 19 domains and features 1365 variant alleles |
| Lag3-203 (ENST00000538079.1) | Transcript length: 2587 bps Retained intron | Retained intron     | Chromosome 12: 6,772,512-6,778,455 | 6 (non-coding) | 2174 variant alleles |
| Lag3-204 (ENST00000541049.1) | Transcript length: 684 bps Retained intron | Retained intron     | Chromosome 12: 6,777,450-6,778,455 | 2 (non-coding) | 404 variant alleles |

The lag-3 gene expresses two canonical transcripts with the same transcription start site. Transcript LAG3-202 results in a truncated version of the full-length protein as a consequence of not having the last three exons. An extended promoter is also predicted. Binding sites for the transcriptional repressor CCCTC-binding factor are predicted (Figure 4).
The genomic annotations of the Lag-3 gene locus. The Lag-3 locus is located at chromosome 12: 6,881,678-6,887,621 forward strand. The illustration shows the organization of the Lag-3 locus (http://grch37.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000089692;r=12:6881678-6887621) [62]. The black bar represents chromosome 12, with positions indicated on top. In green is the Lag-3 coding region. In blue is the transcript retaining one intron. In red is the canonical Lag-3 transcript. In red and blue is the alternatively-spliced Lag-3 transcript. The positions of single-nucleotide polymorphisms are shown below the canonical Lag-3 transcript. The promoter regions are also indicated in pink.

The epigenetic regulation of Lag-3 transcription is largely unknown and might involve DNA methylation [63]. Methylation has been shown to regulate the expression of PD-1, PD-L1, and CTLA-4 in various cancers. For example, methylation of the PD-L1 promoter predicts survival in colorectal cancers, head and neck squamous cell carcinoma, and acute myeloid leukemia [64–66]; PD-1-promoter methylation is associated with recurrence-free survival in prostate cancer [65]; and CTLA-4 methylation correlates to response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma [67]. For instance, a TP53-associated immune prognostic signature (TIPS) is positively correlated with high expression of LAG-3 and other critical immune checkpoint biomarkers in the TCGA cohort [68]. CpG islands in the Lag-3 promoter have been described as highly hypomethylated. Histone 3 lysine 9 (H3K9) and lysine 27 (H3K27) were shown to be trimethylated in human primary breast tumor tissues compared with normal tissues [69]. This was associated with low enrichment of repressive histones in the promoter region. In addition, DNA methylation of the Lag-3 gene correlated with LAG-3 expression by tumor and immune cells, immune cell infiltration, transcriptional activity, and overall survival in clear cell renal cell carcinoma. These results suggested that Lag-3 expression was likely epigenetically regulated via methylation [70]. Lag-3 expression has been described to be negatively regulated by microRNA-146 in cutaneous T cell lymphoma [71]. In addition, class-specific or class-selective histone deacetylase 6 (HDAC6) inhibition downregulated the expression of LAG-3 in T cells from melanoma patients, thus alleviating T cell suppression [72]. Similar effects were reported on TIM-3, PD-1, and PD-L1 expression.

The transcription factor Egr-2 has been shown to control the activities of CD4 CD25- LAG-3+ regulatory T cells, which may be also involved in Lag-3 transcription. Furthermore, IL-10-secreting Egr-2- LAG-3+ CD4 Tregs could be key for the control of peripheral immunity [73]. Moreover, DHEA-Box Helicase 37 (DHX37) expression has been recently correlated with Lag-3 by gene correlation analyses [74].

There is strong evidence showing that LAG-3 protein expression is related to an “epigenetic exhaustion state” in T cells [75]. From these studies, it can be concluded that DNA and histone modifications are certainly involved in LAG-3 upregulation in cancer, suggesting that epigenetic modifications could be useful as a potential predictive biomarker of response to immune checkpoint blockade immunotherapies. Nevertheless, further
studies are needed to clarify the role of methylation in dysfunctional cell immunophenotypes in cancer and to define its role as a potential diagnostic/prognostic biomarker and therapeutic target.

3. LAG-3 in Disease

3.1. Cancer

LAG-3 expression in T cells is generally assumed to be a marker for aggressive progression in a broad spectrum of different human tumors such as melanoma, Hodgkin’s lymphoma, chronic lymphocytic leukemia, colorectal cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, gastric cancer, follicular lymphoma, prostate cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, breast cancer, anal squamous cell carcinoma, pancreatic cancer, oropharyngeal squamous cell carcinoma, and urothelial carcinoma, among others [30,41,42,51,76–87]. Its expression has also been described as a molecular factor driving T cell exhaustion in several cancers such as pancreatic ductal adenocarcinoma [80]. LAG-3-expressing tumors are usually associated with poor survival, although a high expression of LAG-3 is associated with favorable overall survival and disease-free survival in some solid tumors, particularly in early-stages, such as breast cancer, ENKTL nasal type, NSCLC, and TNBC [88].

The past 5 years have seen an improved understanding of the mechanisms underlying resistance to checkpoint inhibition such as upregulation or activation of the alternative immune checkpoints including PD-1, CTLA-4, and LAG-3. LAG-3 and PD-1 co-expression is associated with poor disease prognosis in several malignancies. Its upregulation in tumor antigen-specific T cells implies impaired cell-mediated immunity and marks T cells with proliferative dysfunctionality [42,89]. The prognostic significance of immune checkpoint expression in the microenvironment of primary and metastatic cancers is now a reality.

Cancer patients with high expression of LAG-3 in T lymphocytes show activated apoptotic phenotypes in T cells, which is associated with increased PD-1 expression and poor survival after a PD-1 blockade [90]. PD-1/LAG-3 expression is a marker for exhausted T lymphocytes infiltrating tumors [17], which a high-risk signature, and a clinical factor predictive of overall survival [91,92]. NSCLC patients who do not respond to immunotherapy present highly dysfunctional systemic T lymphocytes that simultaneously express PD-1 and LAG-3 following TCR stimulation. These dysfunctional T lymphocytes are resistant to anti-PD-L1/PD-1 monotherapies, possibly due to the expression of LAG-3 [42]. It has been shown in different experimental models that LAG-3 and PD-1 are co-expressed in TILs from progressing tumors, and that their co-blockade has synergistic effects against immune escape, increased antitumor response, enhanced T cell proliferation, and cytokine production [41,42,56,93,94]. Indeed, the blockade of PD-1/LAG-3 pathways during T-cell priming increases T cell proliferation, cytokine production, and antitumor functions [41]. Overall, these studies suggest that tumors in which immune evasion is predominantly mediated by LAG-3 are less sensitive to a PD-1 blockade. Hence, this opens the possibility of eventually using LAG-3 as a stratifying biomarker in immunotherapy. Several clinical trials are currently ongoing, investigating a combinatorial blockade of immune checkpoints that include LAG-3.

3.2. Parkinson’s Disease

Emerging preclinical and clinical evidence suggests that LAG-3 is associated with an increased risk of Parkinson’s disease (PD) [59]. LAG-3 is expressed in neurons and acts as a binding receptor for the pathologic fibrillary $\alpha$-synuclein, mediating its aggregation, intracellular transmission, and spreading [60]. This process involves pre-formed $\alpha$-synuclein fibrils followed by exogenous endocytosis by LAG-3 engagement on neurons [61].
Some LAG-3 single-nucleotide polymorphism variants have been correlated with increased PD risk, especially in the female population. Soluble LAG-3 in serum and cerebrospinal fluid (CSF) have been shown to associate to PD clinical development and negative progression. Thus, a disruption of the immune homeostasis caused by LAG-3 dysfunction in the central nervous system could initiate neuron-to-neuron α-synuclein aggregation and PD progression. In conclusion, LAG-3 could serve as a possible therapeutic target to slow the progression of α-synucleinopathies.

3.3. Cardiovascular Diseases

LAG-3 protein expression has been shown to correlate with increased coronary heart disease (CHD) and increased myocardial infarction (MI). LAG-3 accumulates in cardiac allografts undergoing rejection episodes to fully vascularized, heterotopic, allogeneic heart transplantation [95]. LAG-3 deficiency has also been associated in clinical studies with increased risk of coronary artery disease (CAD) due to Tr1 dysfunction [96].

3.4. HDL Hypercholesterolemia

LAG-3 protein expression levels have been significantly associated via transcriptomic studies with high HDL cholesterol (HDL-C) and HALP (HDL-C ≥ 60 mg/dl). Indeed, LAG-3 deficiency altered lipid raft formations and cell phosphosignaling, processes leading to an enhanced proinflammatory state, and increased production of inflammatory cytokines such as TNFα [97,98].

3.5. Inflammatory Bowel Disease

LAG-3 has been reported to be a modulator of T cell regulation in inflammatory responses in the intestine [48]. In addition, LAG-3+ regulatory T cells are required to suppress the inflammatory activities of CX3CR1+ macrophages to maintain tissue homeostasis during lymphoid cell-driven colitis [99]. Moreover, LAG-3+ cells have been shown to be increased in the inflamed mucosa and correlate with endoscopic severity and disease phenotype in ulcerative colitis [12].

3.6. Multiple Sclerosis

Germline allelic variation of the LAG-3 gene has been described to confer susceptibility to multiple sclerosis (MS). Particularly, at least three single-nucleotide polymorphism (SNPs) have been significantly (p < 0.05) associated with increased risk of MS, possibly by derangement of immune homeostasis [100]. In this study, three distributions of SNPs were found to be significant for MS susceptibility: rs19922452, rs951818, and rs870849. Rs870849 represents LAG-3 with an amino acid substitution of a nonpolar isoleucine for an uncharged polar threonine (Thr455Ile) that may alter protein function and conformation. SNPs rs19922452 and rs951818 are located in a noncoding region, so their implication in increased risk is unclear. However, this remains to be determined through functional studies of the LAG-3 protein to validate the importance of these results and to identify protective SNP haplotypes.

3.7. Diabetes Mellitus

LAG-3 expression could effectively prevent some autoimmune disorders, as it has been described as limiting the pathogenic potential of CD4 and CD8 T cells in the initiation phase and the driving phase of diabetes onset [101]. In fact, the absence of LAG-3 accelerates autoimmune diabetes [101]. The deletion of LAG-3 resulted in faster autoimmune diabetes development in both male and female, non-obese diabetic (NOD) mice, a model for type 1 diabetes (T1D) in humans. The absence of LAG-3 led to a faster accumulation of T cell infiltration within NOD pancreatic islets. Even a partial reduction in LAG-3 expression led to rapid diabetes disease development. LAG-3 is also important to inhibit
Th1 cell activation, reducing T-cell autoreactivity and T1D [102]. In this case, the therapeutic enhancement of LAG-3 functions could serve as a treatment for T1D.

3.8. LAG-3 in Infection

LAG-3 expression has also been linked to increased pathology in certain infections. High accumulation of LAG-3+ CD138+ natural regulatory plasma cells was associated with impaired control of immunity against Salmonella infection, leading to higher bacterial load and a reduced survival rate [56]. Infection with Plasmodium parasites (P. yoelii 17XL, P. yoelii 17XNL, P. chabaudi, P. vinckeii, and P. berghei) causes increased PD-1 and LAG-3 expression by activated CD4 cells [103]. In fact, CD11a+CD49d+CD4 T cells express PD-1 and LAG-3 during infection with Plasmodium parasites. Interestingly, the in vitro blockade of PD-1/LAG-3 interactions enhanced cytokine production in response to infection. LAG-3 was also shown to be expressed in CD4 T cells and NK cells during active Mycobacterium tuberculosis infections, enhancing high bacterial burdens together with changes in Th1 responses [104]. Accordingly, LAG-3 expression was shown to be increased in the lungs, and particularly within the granulomatous lesions. LAG-3 could also be relevant in human immunodeficiency virus (HIV) infection, as its upregulation is associated with a high viral load within a T cell exhausted subset, correlating with faster disease progression [105]. Nonpathogenic simian immunodeficiency virus (SIV) primary infections induce DNA methylation in the LAG-3 coding gene. A similar mechanism may be occurring in HIV-infected patients, which could contribute to persisting metabolic and inflammation disorders [106].

LAG-3 expression is significantly up-regulated in hepatitis B virus (HBV)-specific CD8 T cells, acting as a suppressor of HBV-specific, cell-mediated immunity or even to the pathogenesis of hepatocellular carcinoma [84]. LAG-3 expression was also correlated with human papillomavirus (HPV) status [81]. Thus, LAG-3 inhibitors may help the immune system, overcoming immune exhaustion to fight viral infections. LAG-3 is also expressed on CD8 T cells during chronic hepatitis C virus (HCV) infection, inhibiting cell proliferation, cytotoxicity function, and cytokine production. LAG-3+ CD4 T cell numbers were negatively associated with HCV-neutralizing antibody responses [87]. Exhausted LAG-3+ CD8 T cells were also associated with other chronic viral infections [107,108]. In agreement with this, lymphocytic choriomeningitis viral (LCMV) and herpes simplex virus 1 (HSV-1) infections also showed an increase in LAG-3 expression after infection [14,109–112].

4. Clinical Landscape of LAG-3-Targeted Therapy

Cancer immunotherapies, including immune checkpoint inhibitor blockades, stimulate the immune system to recognize and eliminate tumor cells and could also be important for enhancing responses toward infectious agents. These therapies act mainly on the reactivation of T lymphocytes. However, not all patients respond to these therapies, which represents a significant clinical, economical, and ethical problem [113–116]. The inhibitory co-receptors that modulate T cell activation during antigen presentation are highly important immune checkpoints. These molecules are generally present in the immune synapse, together with the TCR, and modulate its signal transduction capacities. Some examples are PD-1, CD244, CD160, TIM-3, CTLA-4, and LAG-3 [117]. Particularly, ICIs blocking PD-1/PD-L1 interactions have revolutionized oncology, with very promising results for cancer treatment [118–121]. Due to the efficacy of these ICIs, a set of second-generation ICIs such as anti-LAG-3 antibodies and combinations are being evaluated at the preclinical and clinical levels [7].

LAG-3 was first exploited in clinical trials in 2006 as a LAG-3-Ig fusion protein to take advantage of its immune-stimulating activities as a soluble protein (Eftilagimod alpha, IMP321). Nowadays, there are several LAG-3-antagonistic immunotherapeutics models at various stages of clinical and pre-clinical development (Table 2). In addition, combinations blocking LAG-3 together with other immune checkpoints (PD-1, PD-L1, TIM-3,
CTLA4) are also being studied [108,122]. A new generation of bispecific PD-1/LAG-3 blocking agents have shown strong capacities to specifically target PD-1/LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities [123].

| Phase | Therapy | NCT Identifier | Intervention/Treatment Tested | Condition or Disease |
|-------|---------|----------------|-------------------------------|----------------------|
| Early I | Monotherapy | NCT04566978 | Anti-LAG-3 (89Zr-DFO-REGN3767) | Large B-cell Lymphoma, DLBCL |
|        | Monotherapy | NCT03489369 | Anti-LAG-3 (Sym022) | Metastatic Cancer, Solid Tumor, Lymphoma |
|        | Monotherapy | NCT03965533 | Anti-LAG-3 (GSK2831781) | Healthy Volunteers |
|        | Monotherapy | NCT02195349 | Anti-LAG-3 (GSK2831781) | Psoriasis |
|        | Monotherapy | NCT03538028 | Anti-LAG-3 (INCAGN02385) | Select Advanced Malignancies |
|        | Monotherapy | NCT00351949 | LAG-3-Ig (Eftilagimod Alpha, IMP321) | Metastatic Renal Cell Carcinoma (MRCC) |
|        | Monotherapy | NCT03252938 | LAG-3-Ig (Eftilagimod alpha, IMP321), anti-PD-L1 (Avelumab), standard-of-care chemotherapy | Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasms |
|        | Monotherapy | NCT02658981 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), Anti-CD137 (Urelumab, BMS-663513) | Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasms |
| I | Monotherapy and Combination | NCT03250832 | Anti-LAG-3 (TSR-033), Anti-PD-1 | Advanced Solid tumors, Colorectal Cancer |
|        | Monotherapy and Combination | NCT03005782 | Anti-LAG-3 (REGN3767), Anti-PD-1 (Cemiplimab, REGN2810) | Advanced Cancers |
|        | Monotherapy and Combination | NCT02966548 | Anti-LAG-3 (Retalimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Advanced Solid Tumors |
|        | Combination | NCT00354263 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Agripal Reference Flu Antigen (commercially available flu vaccine) | Healthy Volunteers |
|        | Combination | NCT04658147 | Anti-LAG-3 (Relatlimab), Anti-PD-1 (Nivolumab) | Hepatocellular Carcinoma |
|        | Combination | NCT03219268 | Anti-PD-1/Anti-LAG-3 DART protein MGD013, Anti-HER2 (Margetuximab, MGAH22) | Advanced Solid Tumors, Hematologic Neoplasms, Gastric Cancer, Ovarian Cancer, Gastroesophageal Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer |
|        | Combination | NCT03440437 | Anti-LAG-3/PD-L1 Bispecific Antibody (FS118) | Advanced Cancer, Metastatic Cancer |
|        | Combination | NCT00732082 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Gemcitabine (Gemzar) | Pancreatic Neoplasms |
|        | Combination | NCT03742349 | Anti-LAG-3 (LAG525, IMP701), Anti-PD-L1 (Spartalizumab, PDR001), Anti-A2AR (NIR178), MET inhibitor (capmatinib, INC280), Anti-M-CSF (MCS110), Anti-IL-1-beta (canakinumab, ACZ885) | Triple Negative Breast Cancer (TNBC) |
|        | Combination | NCT04140500 | Anti-PD1-LAG-3 Bispecific Antibody (RO7247669) | Solid Tumors |
| Study ID | Treatment | Primary Tumor Type | Additional Details |
|---------|-----------|-------------------|--------------------|
| NCT03849469 | Anti-CTLA4-LAG-3 Bispecific Antibody (XmAb®22841), Anti-PD-1 (Pembrolizumab (Keytruda®)) | Selected Advanced Solid Tumors | |
| NCT03311412 | Anti-LAG-3 (Sym022), Anti-TIM-3 (Sym023), Anti-PD-1 (Sym021) | Metastatic Cancer, Solid Tumors, Lymphoma | |
| NCT02817633 | Anti-LAG-3 (TSR-033), Anti-PD-1 (TSR-042), Anti-TIM-3 (TSR-022) | Advanced or Metastatic Solid Tumors | |
| NCT04252768 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Metastatic Breast Cancer | |
| NCT02676869 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Anti-PD-1 (Pembrolizumab) | Unresectable or Metastatic Melanoma | |
| NCT03493932 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Metastatic Breast Carcinoma | |
| NCT03044613 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Recurrent Glioblastoma Patients | |
| NCT04618393 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab) | Metastatic Solid Tumor | |
| NCT04611126 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, Opdivo), Carboptatin, Paclitaxel, Radiation | Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer | |
| NCT04641871 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Sym023), Anti-TIM-3 (Sym022) | Advanced Solid Tumor Malignancies | |
| NCT04618393 | Anti-PD-1-LAG-3 Bi-specific Antibody (EMB-02) | Advanced Solid Tumors | |
| NCT04706715 | Anti-LAG-3 (89Zr-DFO-REGN3767), Cemiplimab | Metastatic Solid Tumor | |
| NCT02460224 | Anti-LAG-3 (LAG525), Anti-PD1 (PDR001) | Advanced Solid Tumors | |
| NCT04059294 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), (BMS-986213) | Neoplasms by Site, Solid Tumors | |
| NCT04611126 | Anti-LAG-3 (Relatlimab), Anti-PD-L1 (Ipilimumab), Anti-PD-1 (Nivolumab), Cyclophosphamid, Fluodarabine Phosphate, Tumor Infiltrating Lymphocytes infusion | Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer | |
| NCT04150965 | Anti-LAG-3 (Relatlimab, BMS-986016), Elotuzumab (Empliciti), Pomalidomide, Dexame-thasone, Anti-TIGIT (BMS-986207) | Multiple Myeloma, Relapsed Refractory Multiple Myeloma | |
| NCT04618393 | LAG-3-Ig (ImmuFact-IMP321), Tumor Antigenic Peptides (NA-17, MAGE-3.A2, NY-ESO-1, Melan-A, MAGE-A3, MAGE-A3-DP4), Montanide ISA-51 | Melanoma | |
| NCT0365937 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Immunological peptides and adjuvants, HLA-A2 peptides (Tyrosinase.A2, MAGE-C2.A2, MAGE-3.A2, MAGE-1.A2, NA17.A2 (GnTV), MAGE-10.A2), Montanide ISA51 | Melanoma | |
| NCT03459222 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558), IDO1 Inhibitor (BMS-986205), Anti-CTLA-4 (Ipilimumab, Yervoy, BMS-734016) | Advanced Solid Cancers |
| NCT Number | Study Details |
|------------|--------------|
| NCT02488759 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab), Anti-CTLA4 (Ipilimumab), Anti-CD38 (Daratumumab, Darzalex) | Various Advanced Cancers |
| NCT02061761 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Hematologic Neoplasm (Refractory B-Cell Malignancies) |
| NCT03610711 | Anti-LAG-3 (Relatlimab), Anti-PD-1 (Nivolumab, Optivo) | Gastroesophageal Cancer |
| NCT04370704 | Anti-PD-1 (NCMGA00012), Anti-LAG-3 (INCAGN02385), Anti-TIM-3 (INCAGN02390) | Melanoma |

**Monotherapy**

| NCT Number | Study Details |
|------------|--------------|
| NCT03893565 | Anti-LAG-3 (GSK2831781) | Ulcerative Colitis |
| NCT04080804 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD1 (Nivolumab, OPDIVO), Anti-CTLA4 (Ipilimumab, Yervoy) | Head and Neck Squamous Cell Carcinoma (HNSCC) |

**Combination**

| NCT Number | Study Details |
|------------|--------------|
| NCT04567615 | Anti-LAG-3 (Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD1 (Nivolumab, BMS-936558) | Advanced Hepatocellular Carcinoma |
| NCT03484923 | Anti-LAG-3 IgG4 (LAG525), Anti-PD-1 (Spartalizumab, PDR001), Capmatinib (INC280), Canakinumab (ACZ885), Ribociclib (LEE011) | Melanoma |
| NCT04634825 | PD-IXLAG-3 bispecific DARTmolecule (Tebotelimab, MGD013), Anti-B7-H3 (Eno- blituzumab, MGA271), Anti-PD-1 (Retifanlimab, INCMGA00012, MGA012) | Head and Neck Neoplasms |
| NCT03625323 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Anti-PD-1 (Pembrolizumab, Keytruda, MK-3475) | Non-Small Cell Lung Carcinoma (NSCLC) and Head and Neck Carcinoma (HNSCC) |

**II**

| NCT Number | Study Details |
|------------|--------------|
| NCT03623854 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Chordoma |
| NCT03662659 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558), (BMS-986213), XELOX (Oxaliplatin + capecitabine), FOLFOX (Oxaliplatin + leucovorin + fluorouracil), SOX (Oxaliplatin + tegafur/gimeracil/oteracil potassium) | Gastric or Gastroesophageal Junction (GEJ) Cancers |
| NCT02614833 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Adenocarcinoma Breast Stage IV |
| NCT03365791 | Anti-LAG-3 (LAG525), Anti-PD-1 (PDR001) | Advanced Solid and Hematologic Malignancies |
| NCT02060188 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558) | Colorectal Cancer |
| NCT02519322 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), surgery | Melanoma |
| NCT03642067 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, OPDIVO) | Advanced Colorectal Cancer |
| NCT03607890 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, OPDIVO) | Advanced Mismatch Repair-Deficient Cancers |
5. Conclusions

The lymphocyte-activating gene 3 (LAG-3) is a key regulator of immune homeostasis as a next-generation immune checkpoint. Several LAG-3 blockade immunotherapeutic models are being pursued at various stages of clinical and pre-clinical development. However, the mechanisms leading to LAG-3 inhibitory functions are still poorly understood. This is a major clinical problem and one of the most significant challenges for drug development in immunoncology. The understanding of the mechanisms of PD-1/LAG-3 co-signaling in driving T cell dysfunctionality could help us understand the basis for resistance to immunotherapy and uncover mechanisms to counteract the resistance and benefit from immunotherapies. Indeed, the co-blockade of LAG-3 with PD-1 is showing encouraging results, as recently announced for the treatment of metastatic melanoma in the RELATIVITY-047 phase 3 clinical trial (https://clinicaltrials.gov/ct2/show/NCT03470922, access on 2 May 2021). The combination of relatlimab and nivolumab met the primary endpoint of progression-free survival.

Concluding, a deeper understanding of the basic mechanisms underlying LAG-3 intracellular signaling will provide insight for further development of novel strategies for cancer, infections, autoimmune disorders, and neurological diseases.

Author Contributions: L.C. conceived the review and wrote the first draft. All authors contributed to the article and approved the submitted version. L.C., G.K., and D.E. conceived the review and contributed to the writing of the final version. All authors have read and agreed to the published version of the manuscript.

Funding: The Oncoimmunology group is funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119, FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Project Horizon 2020 Improved Vaccination for Older Adults (ISOLDA; ID: 848166); Crescendo Biologics Ltd.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Huard, B.; Tourmier, M.; Hercend, T.; Triebel, F.; Faure, F. Lymphocyte-Activation Gene 3/Major Histocompatibility Complex Class II Interaction Modulates the Antigenic Response of CD4+ T Lymphocytes. *Eur. J. Immunol.* 1994, 24, 3216–3221.
2. Huard, B.; Prigent, P.; Pagès, F.; Bruniquel, D.; Triebel, F. T Cell Major Histocompatibility Complex Class II Molecules Down-Regulate CD4+ T Cell Clone Responses Following LAG-3 Binding. *Eur. J. Immunol.* 1996, 26, 1180–1186.
3. Workman, C.J.; Dugger, K.J.; Vignali, D.A.A. Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3. *J. Immunol.* 2002, 169, 5392–5395.
4. Workman, C.J.; Rice, D.S.; Dugger, K.J.; Kurschner, C.; Vignali, D.A.A. Phenotypic Analysis of the Murine CD4-Related Glycoprotein, CD223 (LAG-3). *Eur. J. Immunol.* 2002, 32, 2255–2263.
5. Workman, C.J.; Cauley, L.S.; Kim, I.-J.; Blackman, M.A.; Woodland, D.L.; Vignali, D.A.A. Lymphocyte Activation Gene 3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation in Vivo. *J. Immunol.* 2004, 172, 5450–5455.
6. Maçon-Lemaître, L.; Triebel, F. The Negative Regulatory Function of the Lymphocyte-Activation Gene-3 Co-Receptor (CD223) on Human T Cells. *Immunology* 2005, 115, 170–178.

7. Andrews, L.P.; Marciscano, A.E.; Drake, C.G.; Vignali, D.A.A. LAG3 (CD223) as a Cancer Immunotherapy Target. *Immunol. Rev.* 2017, 276, 80–96.

8. Triebel, F.; Jitsukawa, S.; Baixeras, E.; Roman-Roman, S.; Geneeve, C.; Viegas-Pequignot, E.; Hercul, T. LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4. *J. Exp. Med.* 1990, 171, 1393–1405.

9. Baixeras, B.E.; Huard, B.; Miossec, C.; Jitsukawa, S.; Martin, M.; Hercul, T.; Auffray, C.; Triebel, F.; Tonneau-Piatier, D. Characterization of the Lymphocyte Activation Gene 3-Encoded Protein. A New Ligand for Human Leukocyt3- Antigen Class H Antigens. *Pharm. Res.* 1992, 17, 327–337.

10. Annunziato, F.; Manetti, R.; Tomasevíc, I.; Giudizi, M.; Biagiotti, R.; Giannoni, V.; Germano, P.; Mavilia, C.; Maggi, E.; Romagnani, S. Expression and Release of LAG-3-Encoded Protein by Human CD4+ T Cells Are Associated with IFN-γ Production. *FASEB J.* 1996, 10, 769–776.

11. Avice, M.N.; Sarfati, M.; Triebel, F.; Delespesse, G.; Demeure, C.E. Lymphocyte Activation Gene-3, a MHC Class II Ligand Expressed on Activated T Cells, Stimulates TNF-Alpha and IL-12 Production by Monocytes and Dendritic Cells. *Immunol. 1999*, 162, 2748–2753.

12. Slevin, S.M.; Garner, L.C.; Lahiff, C.; Tan, M.; Wang, L.M.; Ferry, H.; Greenaway, B.; Lynch, K.; Geremia, A.; Hughes, S.; et al. Lymphocyte Activation Gene (LAG)-3 Is Associated with Mucosal Inflammation and Disease Activity in Ulcerative Colitis. *J. Crohns Colitis.* 2020, 14, 1446–1461.

13. Hannier, S.; Tournier, M.; Bismuth, G.; Triebel, F. CD3/TCR Complex-Associated Lymphocyte Activation Gene-3 Molecules Inhibit CD3/TCR Signaling. *J. Immunol.* 1998, 161, 4058–4065.

14. Blackburn, S.D.; Shin, H.; Haining, W.N.; Zou, T.; Workman, C.J.; Polley, A.; Betts, M.R.; Freeman, C.J.; Vignali, K.M.; Heale, B.S.; Saftig, P.; Hartmann, D.; Black, R.A.; Rossi, J.J.; Blobel, C.P.; et al. LAG-3 Regulates CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors During Chronic Viral Infection. *Nat. Immunol.* 2009, 10, 29–37.

15. Chihara, N.; Madi, A.; Kondo, T.; Zhang, H.; Acharya, N.; Singer, M.; Nyman, J.; Marjanovic, N.D.; Kowalczyk, M.S.; Wang, C.; et al. Induction and Transcriptional Regulation of the Co-Inhibitory Gene Module in T Cells. *Nature 2018*, 558, 454–459.

16. Grosso, J.F.; Kelleher, C.C.; Harris, T.J.; Maris, C.H.; Hipkiss, E.L.; De Marzo, A.; Anders, R.; Netto, G.; Derese, G.; Bruno, T.C.; et al. LAG-3 Regulates CD8+ T Cell Accumulation and Effector Function in Murine Self—And Tumor-Tolerance Systems. *J. Clin. Invest.* 2007, 117, 3383–3392.

17. Grosso, J.F.; Goldberg, M.V.; Getnet, D.; Bruno, T.C.; Yen, H.-R.; Pyle, K.J.; Hipkiss, E.; Vignali, D.A.A.; Pardoll, D.M.; Drake, C.G. Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells. *J. Immunol.* 2009, 182, 6659–6669.

18. Huang, R.-Y.; Eppolito, C.; Lele, S.; Shrikant, P.; Matsuzaki, J.; Odunsi, K. LAG3 And PD1 Co-Inhibitory Molecules Collaborate to Limit CD8+ T Cell Signaling and Dampen Antitumor Immunity in a Murine Ovarian Cancer Model. *Oncotarget* 2015, 6, 27359.

19. Williams, J.B.; Horton, B.L.; Zheng, Y.; Duan, Y.; Powell, J.D.; Gajewski, T.F. The EGR2 Targets LAG-3 and 4-IBB Describe and Regulate Dysfunctional Antigen-Specific CD8+ T Cells in the Tumor Microenvironment. *J. Exp. Med.* 2017, 214, 381–400.

20. Huard, B.; Mastrangeli, R.; Prigent, P.; Bruniquel, D.; Dorini, S.; El-Tayar, N.; Maigret, B.; Dreano, M.; Triebel, F. Characterization of the Major Histocompatibility Complex Class II Binding Site on LAG-3 Protein. *Proc. Natl. Acad. Sci. USA* 1997, 94, 5744–5749.

21. Li, N.; Workman, C.J.; Martin, S.M.; Vignali, D.A.A. Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Genes-3 (LAG-3; CD223). *Immunol.* 2004, 173, 6806–6812.

22. Li, N.; Wang, Y.; Forbes, K.; Vignali, K.M.; Heale, B.S.; Saftig, P.; Hartmann, D.; Black, R.A.; Rossi, J.J.; Blobel, C.P.; et al. Metalloproteases Regulate T-Cell Proliferation and Effector Function Via LAG-3. *EMBO J.* 2007, 26, 494–504.

23. Mastrangeli, R.; Micangeli, E.; Donini, S. Cloning of Murine LAG3 Lymphocyte Activation Gene 3, May Participate in the Downregulation of the CD3/TCR Activation Pathway. *Eur. J. Immunol.* 2001, 31, 2885–2891.

24. Bae, J.; Lee, S.J.; Park, C.G.; Lee, Y.S.; Chun, T. Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling. *Eur. J. Immunol.* 2014, 193, 3011–3012.

25. Long, L.; Zhang, X.; Chen, F.; Pan, Q.; Phliphatwatchara, P. The Promising Immune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy. *Genes Cancer* 2018, 9, 176.

26. Huard, B.; Prigent, P.; Tournier, M.; Bruniquel, D.; Triebel, F. CD4/Major Histocompatibility Complex Class II Interaction Analyzed with CD4—and Lymphocyte Activation Gene-3 (LAG-3)-Ig Fusion Proteins. *Eur. J. Immunol.* 1995, 25, 2718–2721.

27. Hemon, P.; Jean-Louis, F.; Ramgoml, K.; Brignone, C.; Viguier, M.; Bachelez, H.; Triebel, F.; Charron, D.; Aoudjit, F.; Al-Daccak, R. et al. MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis. *J. Immunol.* 2011, 186, 5173–5183.
31. Donia, M.; Andersen, R.; Kjeldsen, J.W.; Fagone, P.; Munir, S.; Nicoletti, F.; Andersen, M.H.; Straten, P.T.; Svane, I.M. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD8+ T-Cells, which Dampen CD8+ T-Cell Antitumor Reactivity. Cancer Res. 2015, 75, 3747–3759.

32. Chung, I.Y.; Tang, S.J.; Wu, Y.C.; Sun, G.H.; Liu, H.Y.; Sun, K.H. Galectin-3 Augments Tumor Initiating Property and Tumor-igenicity pf Lung Cancer through Interaction with B-Catenin. Oncotarget 2015, 6, 4936–4952.

33. Lu, W.; Wang, J.; Yang, G.; Yu, N.; Huang, Z.; Xu, H.; Li, J.; Qiu, J.; Zeng, X.; Chen, S. et al. Posttranscriptional Regulation of Galectin-3 by miR—128 Contributes to Colorectal Cancer Progression. Oncotarget 2017, 8, 15242–15251, doi:10.18632/oncotarget.14839.

34. Li, M., Feng, Y.M.; Fang, S.Q. Overexpression of Ezrin and Galectin-3 as Predictors of Poor Prognosis of Cervical Cancer. Braz. J. Med. Biol. Res. 2017, 50, doi:10.1590/1414-413120165356.

35. Kouo, T.; Huang, L.; Puscek, A.B.; Cao, M.; Solt, S.; Armstrong, T.; Jaffee, E. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol. Res. 2015, 3, 412–423.

36. Wang, J.; Samnamed, M.F.; Datar, I.; Su, T.T.; Ji, L.; Sun, J.; Chen, L.; Chen, Y.; Zhu, G.; Yin, W.; et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell 2019, 176, 334–347.e12.

37. Huard, B.; Gaulard, P.; Faure, F.; Herceg, T.; Triebel, F. Cellular Expression and Tissue Distribution of the Human LAG-3-Encoded Protein, An MHC Class II Ligand. Immunogenetics 1994, 39, 213–217.

38. Annunzio, F.; Manetti, R.; Cosmi, L.; Galli, G.; Heussner, C.H.; Romagnani, S.; Maggi, E. Opposite Role for Interleukin-10 and Interferon-γ on CD30 and Lymphocyte Activation Gene-3 (LAG-3) Expression by Activated Naïve T Cells. Eur. J. Immunol. 1997, 27, 2239–2244.

39. Bruniquel, D.; Borie, N.; Hannier, S.; Triebel, F. Regulation of Expression of the Human Lymphocyte Activation Gene-3 (LAG-3) Molecule, a Ligand for MHC Class II. Immunogenetics 1998, 48, 116–124.

40. Burton, B.R.; Britton, G.J.; Fang, H.; Verhagen, J.; Smithers, B.; Sabatos-Peyton, C.A.; Carney, L.J.; Gough, J.; Strobel, S.; Wraith, D.C. Sequential Transcriptional Changes Dictate Safe and Effective Antigen-Specific Immunotherapy. Nat. Commun. 2014, doi:10.1038/ncomms5741.

41. Matsuizaki, J.; Gnata, S.; Mwaech-Faucheuglia, P.; Beck, A.; Miller, A.; Tsuji, T.; Eppolito, C.; Qian, F.; Lele, S.; Shrikant, P.; et al. Tumor-Infiltrating NY-ESO-1–Specific CD8+ T Cells are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer. Proc. Natl. Acad. Sci. USA 2010, 107, 7875–7880.

42. Zuazo, M.; Arasan, H.; Fernández-Hinojal, G.; García-Granda, M.J.; Gato, M.; Bocanegra, A.; Martínez, M.; Hernández, B.; Teijeira, L.; Morilla, I. et al. Functional Systemic CD4 Immunity Is Required for Clinical Responses to PD-L1/PD-1 Blockade Therapy. EMBO Mol. Med. 2019, 11, e10293, doi:10.1389/emmm.2020.586907.

43. Huard, B.; Tournier, M.; Triebel, F. LAG-3 Does Not Define a Specific Mode of Natural Killing in Human. Immunol. Lett. 1998, 61, 109–112.

44. Huang, C.T.; Workman, C.J.; Flies, D.; Pan, X.; Marson, A.L.; Zhou, G.; Hipkiss, E.L.; Ravi, S.; Kowalski, J.; Levitsky, H.I.; et al. Role of LAG-3 in Regulatory T Cells. Immunity 2004, 21, 503–513.

45. Gagliani, N.; Magnani, C.F.; Huber, S.; Gianolini, M.E.; Pala, M.; Licona-Limon, P.; Guo, B.; Herbert, D.B.R.; Bulfone, A.; Trentini, F.; et al. Coexpression of CD49b and LAG-3 Identifies Human and Mouse T Regulatory Type 1 Cells. Nat. Med. 2013, 19, 739–746.

46. Allen, J.S.; Larghi, P.; Facciotti, F.; Gagliani, N.; Bosotti, R.; Paroni, M.; Maglie, S.; Gruarin, P.; Vasco, C.M.; Ranzani, V.; et al. Intestinal IFN-γ-Producing Type 1 Regulatory T Cells Coexpress CCR5 and Programmed Cell Death Protein 1 and Downregulate IL-10 in the Inflamed Guts of Patients with Inflammatory Bowel Disease. J. Allergy Clin. Immunol. 2018, 142, 1537–1547.e8.

47. White, A.M.; Wraith, D.C. Tr1-Like T Cells—An Enigmatic Regulatory T Cell Lineage. Front. Immunol. 2016, 7, doi:10.3389/fimmu.2016.00355.

48. Do, J.S.; Visperas, A.; Sanogo, Y.O.; Bechtel, J.J.; Dvorina, N.; Kim, S.; Jang, E.; Stoholm, S.A.; Shen, B.; Fairchild, R.L.; et al. An IL-27-Lag3 Axis Enhances Foxp3+ Regulatory T Cell-Suppressive Function and Therapeutic Efficacy. Mucosal. Immunol. 2016, 9, 137–145.

49. Workman, C.J.; Vignali, D.A.A. Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223). J. Immunol. 2005, 174, 688–695.

50. Camisasihi, C.; Casati, C.; Rini, F.; Perego, M.; De Filippo, A.; Triebel, F.; Parmiani, G.; Belli, F.; Rivoltini, L.; Castelli, C. LAG-3 Expression Defines a Subset of CD4+CD25(High)Foxp3+ Regulatory T Cells That Are Expanded at Tumor Sites. J. Immunol. 2010, 184, 6545–6551.

51. Gandhi, M.K.; Lambley, E.; Duraiswamy, J.; Dua, U.; Smith, C.; Elliott, S.; Gill, D.; Marlton, P.; Seymour, J.; Khanna, R. Expression of LAG-3 by Tumor-Infiltrating Lympheocytes Is Coincident with the Suppression of Latent Membrane Antigen-Specific CD8+ T-Cell Function in Hodgkin Lymphoma Patients. Blood 2006, 108, 2280–2289.

52. Hald, S.M.; Rakaee, M.; Martinez, I.; Richardsen, E.; Al-Saad, S.; Paulsen, E.E.; Blix, E.S.; Kolvaer, T.; Andersen, S.; Busund, L.T.; et al. LAG-3 in Non–small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated with Improved Survival. Clin. Lung Cancer 2018, 19, 249–259.e2.
77. Marcq, E.; De Waeye, J.; Van Audenaerde, J.; Lion, E.; Santerman, E.; Hens, N.; Pauwels, P.; Meerbeeck, J. P. V.; Smits, E. L. J. Abundant Expression Of TIM-3, LAG-3, PD-1 and PD-L1 As Immunotherapy Checkpoint Targets in Effusions of Mesothelioma Patients. *Oncotarget*. 2017, 8, 89722–89735.

78. Burugu, S.; Gao, D.; Leung, S.; Chia, S.K.; Nielsen, T.O. LAG-3+ Tumor Infiltrating Lymphocytes in Breast Cancer: Clinical Correlates and Association with PD-1/PD1+ Tumors. *Ann. Oncol.* 2017, 28, 2977–2984.

79. Yanik, E.L.; Kaunitz, G.J.; Cottrell, T.R.; Succar, F.; McMiller, T.L.; Asciento, M.L.; Esandrio, J.; Xu, H.; Ogurtsova, A.; Cornish, T.; et al. Association of HIV Status with Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. *JAMA Oncol.* 2017, 3, 974–978.

80. Saka, D.; Gökalp, M.; Piyade, B.; Cevik, N.C.; Sever, E.; Unutmaz, D.; Ceyhan, G. O. Demir, I. E.; Asimgil, H.; Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. *Cancers*. 2020, 12, 2274, doi:10.3390/cancers12082274.

81. Wuerdemann, N.; Pütz, K.; Eckel, H.; Jain, R.; Wittekindt, C.; Huebbers, C.U.; Sharma, S. J.; Langer, C.; Gattenlöcher, S.; Büttner, R.; et al. LAG-3, TIM-3 and Vista Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts. *Int. J. Mol. Sci.* 2021, 22, 1–17.

82. Shapiro, M.; Herishanu, Y.; Katz, B.Z.; Dezorella, N.; Vella, A.T.; Manichaikul, A.; Wang, X.; Lymphocyte Activation Gene 3: A Novel Therapeutic Target in Chronic Lymphocytic Leukemia. *Haematol*. 2017, 102, 874–882.

83. Chen, J.; Chen, Z. The Effect of Immune Microenvironment on the Progression and Prognosis of Colorectal Cancer. *Med. Oncol.* 2014, 31, doi:10.1007/s12032-014-0082-9.

84. Li, F.J.; Zhang, Y.; Jin, G.X.; Yao, L.; Wu, D.Q. Expression Of LAG-3 Is Coincided with the Impaired Effector Function of HBV-Specific CD8 + T Cell in HCC Patients. *Immunol. Lett.* 2013, 150, 116–122.

85. Giraldo, N.A.; Becht, E.; Pagès, F.; Skliris, G.; Verkarre, V.; Vano, Y.; Mejean, A.; Saint-Aubert, N.; Lacroix, I.; Natario, I.; et al. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. *Clin. Cancer Res.* 2015, 21, 3031–3040.

86. Takaya, S.; Saito, H.; Ikeguchi, M. Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, On CD4 + and CD8 + T Cells After Gastric Cancer Surgery. *Yonago Acta. Med.* 2015, 58, 39–44.

87. Yang, Z.Z.; Kim, H.J.; Villasboas, J.C.; Chen, Y.P.; Price-Troska, T.P.; Jalali, S.; Wilson, M.; Novak, A. J.; Ansell, S. M.; Expression of LAG-3 Defines Exhaustion of Intratumoral PD-1+ T Cells and Correlates with Poor Outcome in Follicular Lymphoma. *Oncotarget*. 2017, 8, 61425–61439.

88. Saleh, R.R.; Peinado, P.; Fuentes-Antrás, J.; Pérez-Segura, P.; Pandiella, A.; Amir, E.; Ocaña, A.; Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. *Front. Oncol.* 2019, 9, 1040.

89. Wang, Y.; Dong, T.; Xuan, Q.; Zhao, H.; Qin, L.; Zhang, Q. Lymphocyte-Activation Gene 3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. *J. Breast Cancer*. 2018, 21, 124–133.

90. Datar, I.; Sammamed, M.F.; Wang, J.; Hershick, B.S.; Choi, J.; Badri, T.; Dong, W.; Mani, N.; Toki, M.; Mejias, L.D.; et al. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. *Clin. Cancer Res.* 2013, 29, 4663–4673.

91. Sobottka, B.; Moch, H.; Varga, Z. Differential PD-1/LAG-3 Expression and Immune Phenotypes in Metastatic Sites of Breast Cancer. *Breast Cancer Res.* 2021, 23, doi:10.1186/s13058-020-01380-w.

92. Zhang, X.; Zhao, H.; Shi, X.; Jia, X.; Yang, Y. Identification and Validation of an Immune-Related Gene Signature Predictive of Overall Survival in Colon Cancer. *Aging (Albany NY)*. 2020, 12, 26095–26120.

93. Lichtenerg, F.S.; Rothe, M.; Schnorfeil, F.M.; Deiser, K.; Krupka, C.; Augsberger, C.; Schlüter, M.; Neitz, J.; Subklewe, M. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. *Front. Immunol.* 2018, 9, 1–12.

94. Jing, W.; Gershman, J.A.; Weber, J.; Thomak, D.; McOlash, L.; Sabatos-Peyton, C.; Johnson, B. D.; Combined Immune Checkpoint Protein Blockade and Low Dose Whole Body Irradiation as Immunotherapy for Myeloma. *J. Immunother. Cancer*. 2015, 3, doi:10.1186/s40425-014-0043-z.

95. Haudebourg, T.; Dugast, A.S.; Coulon, F.; Usual, C.; Triebel, F.; Vanhove, B. Depletion of LAG-3 Positive Cells in Cardiac Allograft Reveals Their Role in Rejection and Tolerance. *Transplant.* 2007, 84, 1500–1506.

96. Zhu, Z.; Ye, J.; Ma, Y.; Hua, P.; Huang, Y.; Fu, X.; Lie, D.; Yuan, M.; Xiag, Z.; Function of T Regulatory Type 1 Cells Is Down-Regulated and Is Associated with the Clinical Presentation of Coronary Artery Disease. *Hum. Immunol.* 2018, 79, 564–570.

97. Golden, D.; Kolmakova, A.; Sura, S.; Vella, A.T.; Manichaikul, A.; Wang, X.-Q.; Bielinski, S. J.; Taylor, K. D.; Chen, Y. I.; Rich, S. S.; et al. Lymphocyte Activation Gene 3 and Coronary Artery Disease. *JCI Insight*. 2016, 1, 86828.

98. Rodriguez, A. High HDL-Cholesterol Paradox: SCAR3L-LAG3-HDL Axis. Current Atherosclerosis Reports. *Springer*. 2021, 23, doi:10.1007/s11883-020-09902-3.

99. Bauchè, D.; Joyce-Shaik, B.; Jain, R.; Grein, J.; Ku, K.S.; Blumenschein, W.M.; Galan-Vonarburg, S. C.; Wilson, D. C.; McClanahan, T. K.; Malefyit, R.D.W.; et al. LAG3 + Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1 + Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. *Immun. 2018, 49, 342–352.e5.

100. Zhang, Z.; Duveelt, K.; Svensson, F.; Masterman, T.; Jonasdottir, G.; Salter, H.; Emahazion, T.; Hellgren, D.; Falk, G.; Olsson, T.; et al. Two Genes Encoding Immune-Regulatory Molecules (LAG3 And IL7R) Confer Susceptibility to Multiple Sclerosis. *Genes Immun.* 2005, 6, 145–152.

101. Bettini, M.; Szymczak-Workman, A.L.; Forbes, K.; Castellaw, A.H.; Selby, M.; Pan, X.; Drake, C. G.; Korman, A. J.; Dario, A.; Vignali, A.; Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3. *J. Immunol*. 2011, 187, 3493–3498.
102. Delmastro, M.M.; Styche, A.J.; Trucco, M.M.; Workman, C.J.; Vignali, D.A.A.; Piganelli, J.D. Modulation of Redox Balance Leaves Murine Diabetogenic TH1 T Cells “LAG-3-Ing” Behind. Diabetes 2012, 61, 1760–1768.

103. Doe, H.T.; Kimura, D.; Miyakoda, M.; Kimura, K.; Akbari, M.; Yui, K. Expression Of PD-1/LAG-3 and Cytokine Production by CD4 + T Cells During Infection with Plasmidium Parasites. Microbiol. Immunol. 2016, 60, 21–31.

104. Phillips, B.L.; Mehra, S.; Ahsan, M.H.; Selman, M.; Khader, S.A.; Kaushal, D. LAG3 Expression in Active Mycobacterium Tuberculosis Infections. Am. J. Pathol. 2015, 185, 820–833.

105. Graydon, C.G.; Balasko, A.L.; Fowke, K.R. Roles, Function and Relevance of LAG3 in HIV Infection. PLoS Pathog. Public Library of Science 2019, 15, e1007429.

106. Jochens, S.P.; Jacquelin, B.; Tchitchev, N.; Busato, F.; Pichon, F.; Huot, N.; Yi Liu, 5; Ploquin, M. J.; Roché, E.; Cheynier, R.; Dereudre-Bosquet, N.; et al. DNA Methylation Changes in Metabolic and Immune-Regulatory Pathways in Blood and Lymph Node CD4 + T Cells in Response to SIV Infections. Clin. Epigenetics. 2020, 12, doi:10.1186/s13148-020-00971-w.

107. McLane, L.M.; Abdel-Hakeem, M.S.; Wherry, E.J. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Vol. 37, Annual Review of Immunology. Annual Reviews Inc.; 2019. p. 457–95.

108. Anderson, A.C.; Joller, N.; Kuchroo, V.K. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immun. Cell Press 2016, 44, 989–1004.

109. Richter, K.; Agnellini, P.; Oxenius, A. On the Role of the Inhibitory Receptor LAG-3 in Acute and Chronic LCMV Infection. Int. Immunol. 2009, 22, 13–23.

110. Roy, S.; Coulon, P.-G.; Prakash, S.; Srivastava, R.; Geertsema, R.; Dhanushkodi, N.; Lam, C.; Nguyen, V.; Gorospe, E.; Nguyen, A. M.; et al. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8 + T RM Cells and Reduces Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits. J. Virol. 2009, 83, doi:10.1128/JVI.0082719.

111. Roy, S.; Coulon, P.G.; Srivastava, R.; Vadod, H.; Kim, G.J.; Wali, S.S.; Yamada, T.; Foulaudi, M. A.; Ly, V. T.; BenMohamed, L.; Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Antiviral CD8 + T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease. Front. Immunol. 2018, 9, 2922.

112. Liu, Y.; Source, S.; Nuvolone, M.; Domange, J.; Aguzzi, A. Lymphocyte Activation Gene 3 (Lag3) Expression Is Increased in Prion Infections but Does Not Modify Disease Progression. Sci. Rep. 2018, 8, doi:10.1038/s41598-018-32727-8.

113. Martins, F.; Sofiya, L.; Sykiotis, G.P.; Lamine, F.; Maillard, M.; Shabafrouz, K.; Shabafrouz, K.; Ribi, C.; Cairoli, A.; Guex-Crosier, Y.; et al. Adverse effects of immune—checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 2019, 16, 563–580.

114. Nishino, M.; Ramaiya, N.H.; Hatabu, H.; Hodi, F.S. Monitoring Immune-Checkpoint Blockade: Response Evaluation and Biomarker Development. Nat. Rev. Clin. Oncol. 2018, 14, 655–668.

115. Prasad, V.; De Jesús, K.; Mailankody, S. The High Price of Anticancer Drugs: Origins, Implications, Barriers, Solutions. Nat. Rev. Clin. Oncol. 2017, 14, 381–390.

116. Topalian, S.L.; Weiner, G.J.; Pardoll, D.M. Cancer Immunotherapy Comes of Age. J. Clin. Oncol. 2011, 29, 4828.

117. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Perspective Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015, 27, 450–461.

118. Chocarro de Erauso, L.; Zuazo, M.; Arasanz, H.; Bocanegra, A.; Hernandez, C.; Fernandez, G.; Garcia-Granda, M.J.; Blanco, E.; Vera, R.; Kochan, G.; et al. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front. Pharmacol. 2020, 11, doi:10.3389/fphar.2020.00441.

119. Zuazo, M.; Arasanz, H.; Bocanegra, A.; Fernandez, G.; Chocarro, L.; Vera, R.; Kochan, G.; and Escors, D.; Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy Front. Immunol. 2020, 11, doi:10.3389/fimmu.2020.586907.

120. Zuazo, M.; Arasanz, H.; Bocanegra, A.; Chocarro, L.; Vera, R.; Escors, D.; Kagamu, H.; and Kochan, G.; Systemic CD4 Immunity: A Powerful Clinical Biomarker for PD-L1/PD-1 Immunotherapy. EMBO Mol. Med. 2020, 12, e12706.

121. Bocanegra, A.; Fernandez-Hinojal, G.; Zuazo-Ibarra, M.; Arasanz, H.; Garcia-Granda, M.J.; Hernandez, C.; Ibañez, M.; Hernandez-Marín, B.; Martinez-Aguillo, M.; Lecumberri, M.; et al. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. Int. J. Mol. Sci. 2019, 20, doi:10.3390/ijms20071631.

122. Rotte, A.; Jin, J.Y.; Lemaire, V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann. Oncol. 2018, 29, 71–83.

123. Legg, J.W.; McGuinness, B.; Arasanz, H.; Bocanegra, A.; Bartlett, P.; Benedetti, G.; Birkett, N.; Cox, D.; De Juan, E.; Enever, C.; et al. Abstract 930: CB213: A Half-Life Extended Bispecific Humabody V H Delivering Dual Checkpoint Blockade to Reverse the Dysfunction of LAG3 + PD-1 + Double-Positive T Cells. in: Cancer Research. Am. Assoc. Cancer Res. 2020, doi:10.1158/1538-7445.AM2020-930.